Fabhalta Receives FDA Clearance: Redefining PNH Management with Oral Monotherapy

Novartis has achieved a significant regulatory milestone with the FDA’s approval of Fabhalta (iptacopan) as the first oral monotherapy designed specifically for treating paroxysmal nocturnal hemoglobinuria, commonly known as PNH, in adult patients. This breakthrough marks a pivotal moment in complement-mediated disease treatment, offering patients a simplified therapeutic approach compared to existing options. The medication is anticipated to reach patients in the United States during December.

Understanding How Fabhalta Works: The Complement Pathway Mechanism

Fabhalta functions as a Factor B inhibitor, targeting an earlier point in the immune system’s alternative complement pathway—a key pathway responsible for triggering red blood cell destruction both within and outside blood vessels. By intercepting complement activation at this proximal stage, the drug provides comprehensive hemolysis control. This mechanism represents a distinct advantage over previous anti-C5 therapies, which addressed a downstream component of the same pathway. As the only FDA-approved Factor B inhibitor for PNH management, Fabhalta offers patients broader and more complete control over the pathological cascade that defines this chronic blood disorder.

Clinical Evidence: Real-World Patient Benefits from Fabhalta

The FDA’s decision was grounded in robust clinical evidence from two pivotal studies. The Phase III APPLY-PNH trial evaluated Fabhalta’s effectiveness in patients who had residual anemia despite receiving prior anti-C5 treatment, demonstrating that the drug could rescue even treatment-experienced individuals. Simultaneously, the APPOINT-PNH study confirmed efficacy in patients who had never received complement inhibitor therapy. Across both populations, Fabhalta delivered substantial hemoglobin improvements, with nearly all APPLY-PNH participants avoiding blood transfusions—a remarkable outcome that fundamentally changes quality of life for individuals with PNH.

Expanding the Therapeutic Horizon Beyond PNH

Victor Bultó, President of US Operations at Novartis, emphasized that this oral medicine enables patients “to reset their expectations of living with PNH, a chronic and life-altering blood disease.” The company is actively pursuing regulatory approvals and additional clinical investigations worldwide, with Fabhalta also being evaluated in other complement-mediated conditions. This expansion signals Novartis’s commitment to addressing unmet medical needs in rare and severe disorders driven by excessive complement activation.